PMV Pharmaceuticals, Inc.

NasdaqGS:PMVP Stock Report

Market Cap: US$77.6m

PMV Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:PMVP Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
11 Sep 24SellUS$10,853Deepika JalotaIndividual7,218US$1.50
11 Sep 24SellUS$4,347Michael CarulliIndividual2,891US$1.50

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of PMVP?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,109,2242.14%
VC/PE Firms6,475,29112.5%
Hedge Funds6,484,14612.5%
General Public9,652,46918.7%
Institutions28,026,00054.2%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 72.54% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
12.5%
OrbiMed Advisors LLC
6,475,291US$9.7m0%0.14%
7.05%
ArrowMark Colorado Holdings, LLC
3,647,291US$5.5m30%0.07%
6.32%
BML Capital Management, LLC
3,269,907US$4.9m93.6%2.72%
6.21%
Sio Capital Management, LLC
3,214,239US$4.8m18.7%2.32%
5.08%
Euclidean Capital LLC
2,627,643US$3.9m0%0.44%
4.41%
The Vanguard Group, Inc.
2,280,803US$3.4m-0.06%no data
4.02%
Acadian Asset Management LLC
2,078,866US$3.1m0%0.01%
3.89%
PFM Health Sciences, LP
2,011,040US$3.0m57.7%0.2%
3.79%
Alkeon Capital Management, LLC
1,963,132US$2.9m-0.08%0.02%
2.21%
BlackRock, Inc.
1,144,797US$1.7m-1.5%no data
2.04%
Citadel Advisors LLC
1,055,696US$1.6m-38.5%no data
2.01%
D. E. Shaw & Co., L.P.
1,040,477US$1.6m2.04%no data
1.45%
Two Sigma Advisers, LP
751,200US$1.1m52.2%no data
1.36%
Jacobs Levy Equity Management Inc
705,593US$1.1m-9.43%no data
1.25%
David Mack
648,770US$973.2k0%no data
1.06%
Personal CFO Solutions LLC
550,342US$825.5k0%0.12%
1%
Citigroup Inc.,Banking and Securities Investments
514,915US$772.4k-0.14%no data
0.99%
Goldman Sachs Group, Investment Banking and Securities Investments
510,004US$765.0k-35.1%no data
0.93%
Two Sigma Investments, LP
483,055US$724.6k24.4%no data
0.85%
Connor, Clark & Lunn Investment Management Ltd.
441,024US$661.5k0.43%no data
0.85%
Acuitas Investments, LLC
440,687US$661.0k24.6%0.2%
0.85%
Aldebaran Capital, LLC
438,252US$657.4k24.8%0.63%
0.84%
Geode Capital Management, LLC
432,762US$649.1k1.18%no data
0.79%
Arnold Levine
409,842US$614.8k0%no data
0.77%
Wilmington Trust Investment Advisors, Inc.
399,548US$599.3k54.6%0.01%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 19:44
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PMV Pharmaceuticals, Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gregory HarrisonBofA Global Research
Gum-Ming LoweCraig-Hallum Capital Group LLC
Joshua SchimmerEvercore ISI